about
Galactose 6-O-sulfotransferases are not required for the generation of Siglec-F ligands in leukocytes or lung tissueChemical Lectinology: Tools for Probing the Ligands and Dynamics of Mammalian Lectins In VivoSiglecs as sensors of self in innate and adaptive immune responsesAntigen delivery to macrophages using liposomal nanoparticles targeting sialoadhesin/CD169B cell antigen receptor signal strength and peripheral B cell development are regulated by a 9-O-acetyl sialic acid esteraseAntibody-siRNA conjugates: drugging the undruggable for anti-leukemic therapy.Identification and characterization of fully human anti-CD22 monoclonal antibodies.Autoantibody-dependent and autoantibody-independent roles for B cells in systemic lupus erythematosus: past, present, and futureDecoration of T-independent antigen with ligands for CD22 and Siglec-G can suppress immunity and induce B cell tolerance in vivoPossible role of CD22, CD79b and CD20 expression in distinguishing small lymphocytic lymphoma from chronic lymphocytic leukemia.Targeting CD22 with the monoclonal antibody epratuzumab modulates human B-cell maturation and cytokine production in response to Toll-like receptor 7 (TLR7) and B-cell receptor (BCR) signalingIn situ trans ligands of CD22 identified by glycan-protein photocross-linking-enabled proteomics.In vivo targeting of B-cell lymphoma with glycan ligands of CD22.Interaction of platelet endothelial cell adhesion molecule (PECAM) with α2,6-sialylated glycan regulates its cell surface residency and anti-apoptotic role.Epratuzumab targeting of CD22 affects adhesion molecule expression and migration of B-cells in systemic lupus erythematosus.Genetic and functional characterization of the mouse Trl3 locus in defense against tuberculosis.CD22 regulates adaptive and innate immune responses of B cells.Anti-CD22/CD20 Bispecific antibody with enhanced trogocytosis for treatment of Lupus.RNA-Seq Analysis of the Host Response to Staphylococcus aureus Skin and Soft Tissue Infection in a Mouse Model.MicroRNA-19a and CD22 Comprise a Feedback Loop for B Cell Response in Sepsis.A computational model for early events in B cell antigen receptor signaling: analysis of the roles of Lyn and Fyn.CD22 is required for formation of memory B cell precursors within germinal centers.KSGal6ST generates galactose-6-O-sulfate in high endothelial venules but does not contribute to L-selectin-dependent lymphocyte homing.Sialic acids and autoimmune disease.FcgammaRIIB signals inhibit BLyS signaling and BCR-mediated BLyS receptor up-regulation.The generation of influenza-specific humoral responses is impaired in ST6Gal I-deficient miceSiglecs as targets for therapy in immune-cell-mediated disease.A reevaluation of CD22 expression in human lung cancer.Epratuzumab for patients with moderate to severe flaring SLE: health-related quality of life outcomes and corticosteroid use in the randomized controlled ALLEVIATE trials and extension study SL0006.Esterases and autoimmunity: the sialic acid acetylesterase pathway and the regulation of peripheral B cell tolerance.Antibody-based therapy of leukaemia.Mechanism and function of monoclonal antibodies targeting siglec-15 for therapeutic inhibition of osteoclastic bone resorption.Besides an ITIM/SHP-1-dependent pathway, CD22 collaborates with Grb2 and plasma membrane calcium-ATPase in an ITIM/SHP-1-independent pathway of attenuation of Ca2+i signal in B cells.CD22 and autoimmune disease.B-cell targeted therapeutics in clinical development.Mucopolysaccharide diseases: a complex interplay between neuroinflammation, microglial activation and adaptive immunity.Targeting CD22 in B-cell malignancies: current status and clinical outlook.B lymphocytes: development, tolerance, and their role in autoimmunity-focus on systemic lupus erythematosus.In pursuit of a moving target: nanotherapeutics for the treatment of non-Hodgkin B-cell lymphoma.Emerging immunotherapy and strategies directly targeting B cells for the treatment of diffuse large B-cell lymphoma.
P2860
Q24622257-866D08DD-CFE4-45B2-B442-9D73B1A13870Q26800514-A07DC973-92D8-4624-B81C-DE1D7E9E7733Q26829757-7867FD7D-D332-40E0-9F03-F94BAF2A0407Q27301034-13272481-E6D2-4930-A790-74E76909B026Q28304887-06C0E8EF-F07F-4EFA-BA33-DB07F6CAB68EQ30275229-89C819FE-03EB-4F0C-A1FC-CC0FA2E1AEECQ33523255-ABA40D79-DFBF-4111-BF59-38A2F5FF9186Q33601679-44F9523E-4E10-4C99-B557-FDF6B5569052Q33615157-5220B73D-215D-448A-B195-A8D682C381BEQ33683659-2DE57481-6D84-4D7F-9411-0D199630B534Q33691812-95BA6D47-C0E5-4A5C-B763-1FF99062D2DAQ33883072-2032E5A6-52DC-4179-969E-B071535D0733Q33931886-C99F82C5-1228-49D8-8C61-3E2AF4A25FACQ34283441-0270E69C-E8CB-4FB8-832B-F8F4DA844B2BQ34613920-0743EDB5-EF60-4353-A53D-4922A7497B6AQ34993543-89A90766-3399-45DC-937F-2DA170016D89Q35089756-5C7558A0-FC8B-43DA-B908-3AEEE797140DQ35170984-4BD254A5-B116-4FDD-B2BF-B7102061B96DQ35526164-378C689D-CC4D-4B85-94E3-BC51732F1686Q35694299-856BECCB-06C0-44E5-980D-17AF391799F0Q36084264-1FB032FE-E064-4075-BD30-31836023C0B0Q36323954-45003002-F87C-4672-950B-43369F2B11BFQ36563888-4661D029-B61A-404C-BED3-A3CA02B21B65Q36625410-BFFCBCC2-4F3A-40A0-B3B5-1D74ADB363A9Q37100719-1A9E41A6-560F-4C89-B01B-B86D6714ED7AQ37153494-1EFAB796-A99B-467C-B55A-DA4767E36125Q37440061-6817854F-BAE8-4E28-9F9D-D4A67C8FDA70Q37518988-153ED174-1C3F-4246-A745-79CD36EC3D12Q37595993-D18BD0BE-1FCB-46B4-8F55-918BB50D1A8EQ37600303-C27439D5-723E-4BC3-81AC-F35E0397CA16Q37605247-76582187-6EC9-4AF9-970D-C63D612BDD0CQ37622547-1717B333-59B8-4FFA-B04E-066BAE7F806CQ37636595-1B156BFB-3969-41E4-A318-F0AE368CDEF9Q38053491-EA51FA14-5AC7-4751-B976-C76458199C28Q38097162-F3AE6DF3-7315-45E3-8585-F248829CD046Q38105045-F8F4F941-A9DF-4822-B78E-A8E65FD8B489Q38108568-45CF085E-8B37-4CA0-9265-5354AAE441ECQ38159695-06626C81-26A7-4809-AE73-9A482B6E288FQ38253121-468753A7-73AF-4982-90CD-D341BC6149EDQ38311896-E1B57965-C5B7-4067-A016-2B24E43B1164
P2860
description
2008 nî lūn-bûn
@nan
2008 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի մարտին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
CD22: an inhibitory enigma
@ast
CD22: an inhibitory enigma
@en
CD22: an inhibitory enigma
@nl
type
label
CD22: an inhibitory enigma
@ast
CD22: an inhibitory enigma
@en
CD22: an inhibitory enigma
@nl
prefLabel
CD22: an inhibitory enigma
@ast
CD22: an inhibitory enigma
@en
CD22: an inhibitory enigma
@nl
P2860
P3181
P1433
P1476
CD22: an inhibitory enigma
@en
P2093
Jennifer A Walker
Kenneth G C Smith
P2860
P304
P3181
P356
10.1111/J.1365-2567.2007.02752.X
P407
P577
2008-03-01T00:00:00Z